mBER is Manifold Bio's open-source AI framework for designing antibody binders for in vivo drug discovery.
mBER is Manifold Bio's protein design framework for generating antibody binders against selected epitopes and targets. The company describes it as an open-source library built around AlphaFold-Multimer, structural templates, and protein-language-model priors, then validates generated binders through in vivo screening.
Manifold uses mBER with its multiplexed molecular barcoding platform to explore tissue-targeted medicines. The company publishes the code through GitHub and invites partners to create targeted medicines together; the software and its research results remain distinct from any individual therapeutic candidate.
CHAI Discovery
De Novo Antibody Design
chaidiscovery.com
Generate Biomedicines
Generate Platform
generatebiomedicines.com
Evqlv
HyperBind
evqlv.com
| Attribute | mBER | De Novo Antibody Design | Generate Platform | HyperBind | |
|---|---|---|---|---|---|
| Provider | | | | | |
| Founded | 2019 | 2024 | 2018 | 2019 | |
| Sells To | Enterprise | Enterprise | Enterprise | Enterprise | |
| Pricing Model | Licensing | Recurring | Recurring, Software | Recurring, Software | |
| Ownership | Private | Venture-backed | Equity, Venture-backed | Venture-backed |
Provider
Founded 2019
Sells To Enterprise
Pricing Model Licensing
Ownership Private
Provider
Founded 2024
Sells To Enterprise
Pricing Model Recurring
Ownership Venture-backed
Provider
Founded 2018
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Equity, Venture-backed
Provider
Founded 2019
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Venture-backed
EVA combines machine learning and automated laboratory testing to optimize therapeutic antibodies.
Cyrus Platform is Cyrus Biotechnology's computational protein design offering combining AI and Rosetta-based design with laboratory mutagenesis screening.
AI-enabled natural-product drug discovery platform organizing plant chemistry into a searchable library with machine-learning translation and automated screening.
Biology-First AI platform predicts disease-matched compounds using multi-omics human data and functional validation.
Generative protein language model family that jointly reasons over protein sequence, structure, and function to design novel proteins.
EVA combines machine learning and automated laboratory testing to optimize therapeutic antibodies.
Cyrus Platform is Cyrus Biotechnology's computational protein design offering combining AI and Rosetta-based design with laboratory mutagenesis screening.
AI-enabled natural-product drug discovery platform organizing plant chemistry into a searchable library with machine-learning translation and automated screening.
Biology-First AI platform predicts disease-matched compounds using multi-omics human data and functional validation.
Generative protein language model family that jointly reasons over protein sequence, structure, and function to design novel proteins.